{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-257254","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2023-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.187621+00:00","generated_at":"2026-06-09T22:41:33.154166+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Amneal to eliminate Up-C structure, form NewCo; expects $30M annual tax-distribution savings","bullets":["Binding term sheet executed Oct. 16, 2023 to reorganize into single-class structure via new Delaware holding company (NewCo).","All existing Class A and Class B shares convert to NewCo Class A common stock; target completion November 2023.","Six-month 2023 tax-related cash distributions were $30M; elimination expected to improve cash flows and reduce debt.","Tax Receivable Agreement amended: Amneal Legacy Group's share of tax savings reduced from 85% to 75%; no cash consideration.","NewCo to trade under same ticker AMRX on NYSE; management and board unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-257254","json":"https://secwatch.observer/filing/0001193125-23-257254.json","markdown":"https://secwatch.observer/filing/0001193125-23-257254.md","text":"https://secwatch.observer/filing/0001193125-23-257254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000119312523257254/0001193125-23-257254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000119312523257254/d560382d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T22:41:33.154166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30a8f913e4a83a2e9ff09d5ae8e3c6b12425192a","claim":"Amneal Pharmaceuticals, Inc. entered into Term Sheet with holders of the Company's Class B Common Stock (the (effective 2023-10-16).","evidence_excerpt":"On October 16, 2023, Amneal Pharmaceuticals, Inc. (the “Company”), Amneal Pharmaceuticals LLC (the “LLC”), and a representative (the “Amneal Group Representative”) of holders of the Company’s Class B Common Stock, par value $0.01 per share (the “Amneal Legacy Group”), executed a binding term sheet (the “Term Sheet”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000119312523257254/0001193125-23-257254-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"holders of the Company's Class B Common Stock (the"},{"label":"Effective","value":"2023-10-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}